Arca
Skip to content
Tools
Tools

Seizures

Drug research and approvals for seizures: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 158 studies of seizures are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, FDA has 18 approved and 17 open orphan designations naming it, and the EU has 30 authorised medicines for it.

  • Recruiting worldwide: 158
  • Trials authorized in Canada: 10
  • FDA orphan approvals: 18
  • EU medicines: 30

Recruiting now

Newest posted first, of 158 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 29

Phase 3 5

Phase 2 7

  • SelurampanelGlutamate receptor ionotropic AMPA antagonist
  • MidazolamGABA-A receptor; anion channel positive allosteric modulator
  • DarigabatGABA-A receptor; anion channel agonist
  • DoxycyclineMatrix metalloproteinase 7 inhibitor
  • LorazepamGABA-A receptor; anion channel positive allosteric modulator
  • JNJ-40411813Metabotropic glutamate receptor 2 positive allosteric modulator
  • Cannabinol

Phase 1 or earlier 2

  • BumetanideSodium-(potassium)-chloride cotransporter 2 inhibitor
  • ZandatrigineSodium channel protein type VIII alpha subunit inhibitor

How its trials ended

855 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 261 whose ending is known, 50% met their primary endpoint, 7% missed it and 43% stopped early.

  • Completed, result not reported34640%
  • Ongoing17420%
  • Met its primary endpoint13015%
  • Status unknown749%
  • Stopped: other or unclear546%
  • Stopped: enrollment or feasibility263%
  • Missed its primary endpoint182%
  • Stopped: sponsor or business decision162%
  • Stopped: lack of efficacy121%
  • Stopped: safety3<1%
  • Stopped: funding2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Dec 27, 2024A double-blind, randomized, multicenter trial evaluating the efficacy and safety of PRAX-628 in adults with focal seizures (power 1)Vormatrigine (PRAX-628)Praxis Precision MedicineOngoing
Nov 27, 2023A phase 3b/4, interventional, multicenter, open-label, single-arm study to assess behavioral and other co-occurring outcomes following treatment with…CannabidiolJazz PharmaceuticalsClosed
Mar 22, 2023A multicenter, open-label, long-term, safety, tolerability, and efficacy study of XEN1101 in subjects diagnosed with epilepsyAzetukalner (XEN1101)Xenon Pharmaceuticals IncOngoing
Mar 9, 2023A randomized, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the safety, tolerability, and efficacy of XEN1101 as adjunctive therapy…Azetukalner (XEN1101)Xenon Pharmaceuticals IncOngoing
Dec 16, 2022A randomized, double-blind, placebo-controlled, multicenter phase 3 study to evaluate the safety, tolerability, and efficacy of XEN1101 as adjunctive therapy…Azetukalner (XEN1101)Xenon Pharmaceuticals IncClosed
Jun 27, 2019Decreasing postoperative blood loss by topical vs. intravenous tranexamic acid in open cardiac surgery (deposition) trialTranexamic acidHamilton Health Sciences CorporationOngoing
Mar 23, 2018An open label, multicenter, extension study to evaluate the safety and efficacy of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects…Padsevonil (UCB0942)UCBClosed
Feb 10, 2017An open-label, multicenter study with an extension phase to evaluate the safety, tolerability, and exposure-efficacy relationship of perampanel oral suspension…PerampanelEisaiClosed
Feb 2, 2017An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the…Everolimus (RAD001)Novartis PharmaceuticalsClosed
May 28, 2013A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients…Everolimus (RAD001)Novartis PharmaceuticalsClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 35
Nov 17, 2022SezabyTreatment of neonatal seizures in term and preterm infantsSun Pharmaceutical Industries, Inc.Approved
Jul 14, 2022DiacomitTreatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg…BiocodexApproved
Jun 1, 2022ZtalmyTreatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and olderImmedica Pharma ABApproved
Mar 25, 2022FinteplaTreatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and olderUCB, Inc.Approved
Jul 31, 2020EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients…Jazz Pharmaceuticals Research UK LimitedApproved
Jul 31, 2020EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of…Jazz Pharmaceuticals Research UK LimitedApproved
Jul 31, 2020EpidiolexTreatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients…Jazz Pharmaceuticals Research UK LimitedApproved
Jun 25, 2020FinteplaFintepla (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.UCB, Inc.Approved
Jan 10, 2020ValtocoAcute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that…Neurelis Pharmaceuticals, Inc.Approved
May 17, 2019NayzilamNAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters,…UCB, Inc.Approved
Sep 28, 2018EpidiolexEPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2…Jazz Pharmaceuticals Research UK LimitedApproved
Sep 28, 2018EpidiolexEPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2…Jazz Pharmaceuticals Research UK LimitedApproved
Aug 20, 2018DiacomitDIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking…BiocodexApproved
Apr 10, 2018AfinitorFor the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated…Novartis Pharmaceuticals Corp.Approved
Oct 7, 2016CarnexivReplacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following…Lundbeck LLCApproved

Medicines authorised in the EU

Newest first; 15 of 30
Jul 26, 2023ZtalmyGanaxolone · orphanMarinus Pharmaceuticals Emerald LimitedEMA ↗
May 31, 2023Lacosamide AdroiqLacosamide · genericExtrovis EU LtdEMA ↗
Mar 26, 2021OntozryCenobamateAngelini Pharma S.p.AEMA ↗
Dec 18, 2020FinteplaFenfluramine · orphanUCB Pharma S.A.EMA ↗
Sep 19, 2019EpidyolexCannabidiol · orphanJazz Pharmaceuticals Ireland LimitedEMA ↗
Aug 26, 2019Lacosamide UCBLacosamideUCB Pharma S.A.EMA ↗
Sep 18, 2017Lacosamide AccordLacosamide · genericAccord Healthcare S.L.U.EMA ↗
Mar 31, 2016Zonisamide Viatris (previously Zonisamide Mylan)Zonisamide · genericViatris LimitedEMA ↗
Jan 13, 2016Briviact (in Italy: Nubriveo)BrivaracetamUCB Pharma SAEMA ↗
Aug 28, 2015Pregabalin AccordPregabalin · genericAccord Healthcare S.L.U.EMA ↗
Jul 17, 2015Pregabalin ZentivaPregabalin · genericZentiva k.s.EMA ↗
Jun 24, 2015Pregabalin Viatris (previously Pregabalin Mylan)Pregabalin · genericViatris LimitedEMA ↗
Jun 19, 2015Pregabalin SandozPregabalin · genericSandoz GmbHEMA ↗
Jan 7, 2014Levetiracetam HospiraLevetiracetam · genericPfizer Europe MA EEIGEMA ↗
Jul 23, 2012FycompaPerampanelEisai GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.